Biochemical (prostate-specific antigen) relapse-free survival and toxicity after 125I low-dose-rate prostate brachytherapy.

OBJECTIVE: To report our clinical experience and 5-year prostate-specific antigen (PSA) relapse-free survival rate for early-stage prostate cancer after (125)I low-dose-rate prostate brachytherapy. PATIENTS AND METHODS: In all, 300 patients were treated between March 1999 and April 2003, and follow...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Khaksar, S, Laing, R, Henderson, A, Sooriakumaran, P, Lovell, D, Langley, SE
Aineistotyyppi: Journal article
Kieli:English
Julkaistu: 2006

Samankaltaisia teoksia